ASCO26: Platinum-Resistant ADC Leader Elahere Stumbles in Platinum-Sensitive Disease

Why It Matters

The result stalls AbbVie’s strategy to broaden Elahere’s market beyond platinum‑resistant ovarian cancer, limiting revenue growth and opening the field to competing ADCs and biomarker‑agnostic therapies.

Key Takeaways

• Elahere missed PFS benefit in platinum‑sensitive ovarian cancer trial
• Response rate hit 66% yet failed to extend survival
• Higher neuropathy and ocular toxicity observed with Elahere‑carboplatin combo
• Label expansion into platinum‑sensitive disease now uncertain

Pulse Analysis

Elahere (mirvetuximab soravtansine‑gynx) is the first FDA‑approved antibody‑drug conjugate that targets folate‑receptor alpha (FRα), a protein overexpressed in roughly 70 % of high‑grade serous ovarian cancers. By linking the cytotoxic agent DM4 to an FRα‑directed antibody, the drug delivers chemotherapy directly into tumor cells while sparing most normal tissue, a strategy that has driven its strong safety profile and $690 million 2025 sales. The molecule’s success in platinum‑resistant disease positioned it as a potential bridge into earlier‑line, platinum‑sensitive settings, prompting AbbVie to pursue a label expansion.

The Phase II MIROVA trial, presented at ASCO 2026, compared Elahere plus carboplatin with standard platinum chemotherapy followed by a PARP inhibitor. Although the combination achieved a 66.2 % confirmed overall response rate versus 32.8 % for the control, median progression‑free survival was essentially identical—9.53 versus 9.79 months (HR 1.0). Moreover, patients experienced more neuropathy and ocular events, eroding the tolerability advantage that had differentiated Elahere. The neutral PFS outcome dampens AbbVie’s near‑term hopes for a $2.6 billion 2032 sales target that relied on a successful platinum‑sensitive indication.

The setback opens space for biomarker‑agnostic ADCs such as Daiichi Sankyo’s raludotatug deruxtecan, the AstraZeneca/Daiichi Sankyo Datroway, and Gilead’s Trodelvy, all of which aim to capture a broader ovarian‑cancer population without FRα testing. Meanwhile, Corcept’s relacorilant, recently approved for platinum‑resistant disease, could compete by re‑sensitizing tumors to platinum agents. AbbVie still holds a competitive edge with Phase III overall‑survival data from the MIRASOL study and a pipeline of combination regimens, but the MIROVA result signals that future growth will depend on new indications or next‑generation ADC platforms rather than a straightforward label extension.